Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 09/16/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 08/06/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
101 |
| 08/06/20 | 8-K | Current report filing |
|
7 | |
| 07/21/20 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
12 | |
| 06/03/20 | 8-K | Current report filing |
|
34 | |
| 05/28/20 | 8-K | Current report filing |
|
20 | |
| 05/12/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
93 |
| 05/12/20 | 8-K | Current report filing |
|
8 | |
| 05/06/20 | 8-K | Current report filing |
|
3 | |
| 04/23/20 | DEF 14A | Definitive proxy statements |
|
41 |
